Hodgkin’s Lymphoma- a Review: Future Directions in the Era of Targeted Therapy

Haematology Journal of Bangladesh

View Publication Info
 
 
Field Value
 
Title Hodgkin’s Lymphoma- a Review: Future Directions in the Era of Targeted Therapy
 
Creator Islam, Amin
Rahman, Md. Mahabubur
Cervi, Paul
Yeo, J H
 
Subject Hodgkin lymphoma
allogeneic stem cell transplantation
antibody-drug conjugate
brentuximab
immunotherapy
positron emission tomography (PET)-adapted therapy
programmed death 1 (PD-1) inhibitor
 
Description Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed-Sternberg cells in an inflammatory background. Patients are commonly diagnosed in their 20s with a small proportion of patients in their 70s. Patients usually present with supra-diaphragmatic lymphadenopathy with or without associated systemic B symptoms. Even in advanced disease, HL is highly curable with combination chemotherapy, or combined-modality treatment. Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk-adapted approaches have helped de-escalate therapy in low-risk patients while intensifying treatment for higher risk patients. Limited stage disease without risk factors (RFs), are frequently treated with two cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) followed by 20Gy involved-field or -site radiotherapy (IF/IS-RT). In patients with early-stage unfavorable disease, four cycles of chemotherapy are usually consolidated with 30Gy IF/IS-RT. Compared to 4xABVD, 2 cycles of escalated BEACOPP followed by 2 cycles of ABVD ("2+2") improved 5-year progression-free survival with similar 5-year overall survival. Recently, treatment strategies based on 18FDG positron emission tomography response were evaluated. PET-guided omission of RT can constitute a valid therapeutic option in patients with an increased risk of RT-associated toxicity. There are an increasing number of salvage therapies available to patients who are not cured with initial therapy. These include alternative chemotherapy combinations, the novel antibody-drug conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem cell transplantation. The programmed death-1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL.
 
Publisher Haematology Society of Bangladesh
 
Date 2020-05-24
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
text/html
 
Identifier https://journal.hematologybd.org/index.php/haematoljbd/article/view/44
10.37545/haematoljbd201944
 
Source Haematology Journal of Bangladesh; Vol. 3 No. 02 (2019); 50-59
2707-1405
2523-1219
 
Language eng
 
Relation https://journal.hematologybd.org/index.php/haematoljbd/article/view/44/132
https://journal.hematologybd.org/index.php/haematoljbd/article/view/44/133
 
Rights Copyright (c) 2019 Amin Islam, Md. Mahabubur Rahman, Paul Cervi, J H Yeo
https://creativecommons.org/licenses/by-nc/4.0
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library